Salute e Benessere
Xeltis successfully passes evaluation phase for €10million investment from European Innovation Council
Only seven companies, including Xeltis, were successful in securing funding, with Xeltis selected as the only life science company among the cohort. To be selected, companies were required to demonstrate high levels of innovation and technological excellence, the potential for significant market, societal and economic impact, as well as execution capabilities. As part of the award, Xeltis will also receive the STEP Seal which allows access to complementary or alternative funding, in addition to EIC Business Acceleration Services.
This funding will be used to support the Company's clinical advancement and preparations for the commercialization of its groundbreaking bioresorbable vascular conduits.
aXess is a restorative vascular access conduit which enables the creation of new, long-term living vessels for hemodialysis vascular access. It combines the safety and patency of a fistula with the speed to treatment of an AV graft while avoiding the frequent reinterventions and complications, such as infections, associated with current treatment options. Currently, Xeltis is advancing pivotal trials for aXess in both the EU, where enrolment was recently completed, and the US.
Xeltis is a medtech company developing transformative implants that enable the natural creation of living and long-lasting vessels. Xeltis seeks to address the limitations of currently available options for the millions of people requiring hemodialysis access grafts or cardiovascular replacements every year. The Company's proprietary endogenous tissue restoration (ETR) platform utilizes an advanced polymer implant which regenerates the patient's own tissue before gradually being absorbed and leaving new, living, and long-lasting vessels in place. Xeltis' most advanced product currently under clinical development is aXess , an implantable blood vessel for hemodialysis vascular access. Xeltis' groundbreaking technology has high potential to be applied to other major vascular and cardiovascular diseases.
Xeltis is based in The Netherlands and the USA . Its investors include DaVita Venture Group, EQT Life Sciences, Kurma Partners, VI Partners, Ysios Capital, Grand Pharma Group, the European Innovation Council and Invest-NL, in addition to other public and private investors.
Visit the Xeltis website for more details: https://xeltis.com/
View original content:https://www.prnewswire.co.uk/news-releases/xeltis-successfully-passes-evaluation-phase-for-10million-investment-from-european-innovation-council-302422159.html